These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8590312)

  • 1. Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553.
    Tang H; Welton A; Ganea D
    J Interferon Cytokine Res; 1995 Nov; 15(11):993-1003. PubMed ID: 8590312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP.
    Tang H; Sun L; Xin Z; Ganea D
    Ann N Y Acad Sci; 1996 Dec; 805():768-78. PubMed ID: 8993475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies.
    O'Donnell M; Garippa RJ; Rinaldi N; Selig WM; Simko B; Renzetti L; Tannu SA; Wasserman MA; Welton A; Bolin DR
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1282-8. PubMed ID: 7932180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
    Martinez C; Delgado M; Gomariz RP; Ganea D
    J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFN gamma from stimulated murine T lymphocytes.
    Ganea D; Sun L
    J Neuroimmunol; 1993 Sep; 47(2):147-58. PubMed ID: 8103776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism.
    Wang HY; Xin Z; Tang H; Ganea D
    J Immunol; 1996 May; 156(9):3243-53. PubMed ID: 8617946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
    Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
    J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
    Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
    Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms.
    Wang HY; Jiang X; Gozes I; Fridkin M; Brenneman DE; Ganea D
    Regul Pept; 1999 Oct; 84(1-3):55-67. PubMed ID: 10535409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis.
    O'Donnell M; Garippa RJ; Rinaldi N; Selig WM; Tocker JE; Tannu SA; Wasserman MA; Welton A; Bolin DR
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1289-94. PubMed ID: 7932181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of substance P and vasoactive intestinal peptide on interferon-gamma and interleukin-4 production in severe atopic dermatitis.
    Kang H; Byun DG; Kim JW
    Ann Allergy Asthma Immunol; 2000 Sep; 85(3):227-32. PubMed ID: 11030278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex.
    Sun L; Ganea D
    J Neuroimmunol; 1993 Oct; 48(1):59-69. PubMed ID: 7901234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mouse T-cell proliferation by CGRP and VIP: effects of these neuropeptides on IL-2 production and cAMP synthesis.
    Boudard F; Bastide M
    J Neurosci Res; 1991 May; 29(1):29-41. PubMed ID: 1653367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of T lymphocyte proliferation in mice infected with Schistosoma mansoni: VIP suppresses mitogen- and antigen-induced T cell proliferation possibly by inhibiting IL-2 production.
    Metwali A; Blum A; Mathew R; Sandor M; Lynch RG; Weinstock JV
    Cell Immunol; 1993 Jun; 149(1):11-23. PubMed ID: 8099848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury.
    Luo Q; Wang Y; Feng D; Xu Y; Xu L
    Eur J Pharmacol; 2009 Apr; 607(1-3):226-33. PubMed ID: 19222997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex.
    Xin Z; Tang H; Ganea D
    J Neuroimmunol; 1994 Oct; 54(1-2):59-68. PubMed ID: 7929804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside-Ro enhances cell proliferation and modulates Th1/Th2 cytokines production in murine splenocytes.
    Yu JL; Dou DQ; Chen XH; Yang HZ; Hu XY; Cheng GF
    Yao Xue Xue Bao; 2005 Apr; 40(4):332-6. PubMed ID: 16011261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages.
    Larocca L; Calafat M; Roca V; Franchi AM; Leirós CP
    Int Immunopharmacol; 2007 Oct; 7(10):1343-9. PubMed ID: 17673149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.